Submit

Login Login

Register Register

Home / Journals / OR / Special Issue / Long noncoding RNAs as Tumorigenic Drivers and Therapeutic Targets
Journal Menu
Special Issues
Table of Content

All issues

Online First

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

Long noncoding RNAs as Tumorigenic Drivers and Therapeutic Targets

Submission Deadline: 30 October 2025 (closed) View: 1018 Submit to Journal

Guest Editor(s)

Tao Liu, Children’s Cancer Institute Australia & The University of New South Wales, Australia. Email: tliu@ccia.unsw.edu.au
Xu Dong Zhang, University of Newcastle Australia, Australia. Email: xu.zhang@newcastle.com.au

Summary

Long noncoding RNAs (lncRNAs) are emerging as critical tumorigenic factors and therapeutic targets in the past decade. Originally regarded as transcriptional junks, lncRNAs have been demonstrated to regulate gene transcription, mRNA stability, degradation, protein translation and stability/degradation, leading to aberrant expression of tumor suppressors and oncogenic factors. LncRNAs therefore play important roles in malignant transformation, cancer cell proliferation, survival, migration, metastasis, tumor initiation, tumor progression, and cancer cell resistance to anticancer therapies. There are several ways to target lncRNAs: suppressing gene transcription and RNA stability/decay, gene editing with CRISPR–Cas9 or CRISPR–Cas13, disrupting secondary structure, or suppressing the interaction between lncRNAs and binding proteins. Recently, small molecule compounds have been developed to block lncRNA interaction with proteins important for its decay, disrupt the lncRNA motif important for lncRNA stabilization, or block the interaction between lncRNAs and their binding proteins important for their functions. This special issue welcomes manuscript on the role of lncRNAs in tumorigenesis and lncRNA therapies.

Keywords

Long noncoding RNAs (lncRNAs); tumorigenic; therapeutic targets; oncogenic; malignant transformation

Published Papers

Show export options

  • Open Access

    ARTICLE

    Exosomes-Transferred lncRNA H19 Reverses Osimertinib Resistance by Upregulating PTEN via Sponging miR-148-3p in Non-Small Cell Lung Cancer

    Weixiang Song, Yanbo Zhang, Xubo Shen, Qin Yu, Yujin Liu, Yongchun Yu, Rui Chen
    Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078665
    （This article belongs to the Special Issue: Long noncoding RNAs as Tumorigenic Drivers and Therapeutic Targets)
    Abstract Objective: Osimertinib can selectively inhibit both epidermal growth factor receptor (EGFR) sensitizing and T790M gatekeeper mutations, and has shown remarkable therapeutic effects in patients with lung adenocarcinoma. However, almost all patients inevitably develop drug resistance. Herein, we sought to clarify the roles of exosomal lncRNA H19 in modulating osimertinib resistance, focusing on the PI3K-PTEN-Akt signaling axis. Methods: Functional assays, including cell viability assay, colony formation, cell apoptosis and xenograft mouse, employed in evaluate the effects of exosomal lncRNA H19 on cell growth and apoptosis. RNA quantitation and western blot were adopted to demonstrate the regulatory roles of… More >

    View

    284

    Download

    66

  • Open Access

    ARTICLE

    Development and Assessment of a Novel Palmitoylation-Related lncRNA Signature for Prognosis and Immune Landscape in Hepatocellular Carcinoma

    Zhilong He, Jing Qin, Sixuan Wu, Xian Liang, Yu Liu, Jinfeng Qiu, Zhimin Li, Kai Hu
    Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.070567
    （This article belongs to the Special Issue: Long noncoding RNAs as Tumorigenic Drivers and Therapeutic Targets)
    Abstract Objective: The contribution of long non-coding RNAs (lncRNAs) associated with protein palmitoylation to the progression of hepatocellular carcinoma (HCC) remains largely unclear. This study sought to establish a prognostic signature based on palmitoylation-related lncRNAs and explore their functional implications in HCC. Methods: RNA sequencing and clinical data for HCC and normal tissues were sourced from the Cancer Genome Atlas (TCGA). Pearson correlation analysis was used to identify lncRNAs that were co-expressed with palmitoylation-related genes. Univariate Cox regression was applied to select lncRNAs with prognostic value, followed by the construction of a predictive model using the… More >

    View

    1664

    Download

    637

  • Open Access

    ARTICLE

    Long noncoding RNA LINC01106 promotes lung adenocarcinoma progression via upregulation of autophagy

    GENGYUN SUN, YIPING ZHENG, JIANFENG CAI, JIE GAO, LIE DONG, XIANGBIN ZHANG, YINGHUI HUANG
    Oncology Research, Vol.33, No.1, pp. 171-184, 2025, DOI:10.32604/or.2024.047626
    （This article belongs to the Special Issue: Long noncoding RNAs as Tumorigenic Drivers and Therapeutic Targets)
    Abstract Background: Long noncoding RNA, LINC01106 exhibits high expression in lung adenocarcinoma (LUAD) tumor tissues, but its functional role and regulatory mechanism in LUAD cells remain unclear. Methods: LINC01106 expression was analyzed in LUAD tissues and its functional impact on LUAD cells was assessed. LUAD cells were silenced with sh-LINC01106 and injected into nude mice to investigate tumor growth. The downstream transcription factors and molecular mechanism were determined using the Human transcription factor database (TFDB) database and Gene Expression Profiling Interactive Analysis (GEPIA) database. Additionally, the impact of linc01106 on autophagy was analyzed by determining the… More >

    Graphic Abstract

    Long noncoding RNA LINC01106 promotes lung adenocarcinoma progression via upregulation of autophagy

    View

    3423

    Download

    1544

Copyright© 2026 Tech Science Press
© 1997-2026 TSP (Henderson, USA) unless otherwise stated

Share Link